| Literature DB >> 27928223 |
Woong Gil Choi1, Soo Hyun Kim1, Seung-Woon Rha2, Kang-Yin Chen3, Yong-Jian Li4, Byoung Geol Choi2, Se Yeon Choi2, Jin Won Kim2, Eung Ju Kim2, Chang Gyu Park2, Hong Seog Seo2, Dong Joo Oh2.
Abstract
BACKGROUND: Smoking and other risk factors have been well known as important factors of variant angina or coronary artery spasm (CAS). However, clinical features related to age on coronary artery spasm have been rarely evaluated.Entities:
Keywords: Acetylcholine; Age factor; Coronary vasospasm
Year: 2016 PMID: 27928223 PMCID: PMC5131196 DOI: 10.11909/j.issn.1671-5411.2016.10.005
Source DB: PubMed Journal: J Geriatr Cardiol ISSN: 1671-5411 Impact factor: 3.327
The baseline characteristics of the study groups.
| Variables | Group I (< 45 yrs) ( | Group II (45−54 yrs) ( | Group III (55−64 yrs) ( | Group IV (≥ 65 yrs) ( | |
| Age, yrs | 36.7 ± 7.3 | 50.4 ± 2.8 | 59.9 ± 2.9 | 71.1 ± 4.6 | < 0.001 |
| Male | 507 (61.5%) | 630 (49.5%) | 510 (40.1%) | 340 (36.3%) | < 0.001 |
| BMI, kg/m2 | 23.9 ± 3.7 | 24.3 ± 3.1 | 24.5 ± 2.9 | 24.2 ± 3.3 | 0.05 |
| DM | 36 (4.4%) | 121 (9.5%) | 187 (14.7%) | 175 (18.7%) | < 0.001 |
| HTN | 209 (25.3%) | 493 (38.8%) | 670 (52.7%) | 566 (60.5%) | < 0.001 |
| Dyslipidemia | 62 (7.5%) | 169 (13.3%) | 214 (16.8%) | 171 (18.3%) | < 0.001 |
| Smoking | 283 (34.3%) | 312 (24.5%) | 208 (16.4%) | 95 (10.1%) | < 0.001 |
| Laboratory finding | |||||
| hs-CRP, mg/dL | 2.3 ± 7.7 | 2.2 ± 6.5 | 2.8 ± 10.4 | 4.6 ± 14.6 | < 0.001 |
| TC, mg/dL | 170.3 ± 44.3 | 179.0 ± 44.9 | 178.9 ± 46.8 | 174.3 ± 46.7 | 0.944 |
| TG, mg/dL | 122.2 ± 102.5 | 127.6 ± 97.8 | 124.8 ± 87.3 | 117.74 ± 78.3 | 0.083 |
| LDL-C, mg/dL | 104.8 ± 37.7 | 109.72 ± 39.3 | 108.8 ± 39.91 | 103.1 ± 39.8 | 0.472 |
| HDL-C, mg/dL | 50.0 ± 15.3 | 50.73 ± 14.8 | 49.9 ± 15.0 | 49.7 ± 15.1 | 0.426 |
| Medication history | |||||
| Aspirin | 4 (0.5%) | 7 (0.6%) | 25 (2.0%) | 28 (3.0%) | < 0.001 |
| Cilostazol | 0 (0%) | 3 (0.2%) | 9 (0.9%) | 12 (1.3%) | < 0.001 |
| β-blockers | 16 (1.9%) | 25 (2.0%) | 38 (3.0%) | 44 (4.7%) | < 0.001 |
| CCB | 39 (4.7%) | 89 (7.0%) | 105 (8.3%) | 79 (8.4%) | 0.008 |
| ACEi | 8 (1.0%) | 10 (0.8%) | 14 (1.1%) | 11 (1.2%) | 0.797 |
| ARB | 19 (2.3%) | 54 (4.2%) | 75 (5.9%) | 48 (5.1%) | 0.008 |
| Nitrates | 156 (18.9%) | 228 (17.9%) | 234 (18.4%) | 150 (16.0%) | 0.389 |
| Nicorandil | 4 (0.5%) | 21 (1.7%) | 27 (2.1%) | 34 (3.6%) | < 0.001 |
| Statins | 18 (2.2%) | 73 (5.7%) | 93 (7.3%) | 73 (7.8%) | < 0.001 |
Data are presented as mean ± SD or n (%). ACEi: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; BMI: body mass index; CCB: calcium channel blockers; DM: diabetes mellitus; HDL-C: high density lipoprotein cholesterol; hs-CRP: high sensitivity C reactive protein; HTN: hypertension; LDL-C: low density lipoprotein cholesterol; TC: total cholesterol; TG: triglyceride.
Characteristics of Ach provocation test in study population.
| Variables | Group I (< 45 yrs) ( | Group II (45−54 yrs) ( | Group III (55−64 yrs) ( | Group IV (≥ 65 yrs) ( | |
| RD after NTG infusion, mm | 2.51 ± 0.58 | 2.45 ± 0.60 | 2.42 ± 0.91 | 2.27 ± 0.53 | < 0.001 |
| MD after Ach infusion, mm | 0.76 ± 0.36 | 0.70 ± 0.37 | 0.69 ± 0.38 | 0.66 ± 0.32 | < 0.001 |
| DN after Ach infusion | 69.9% ± 12.8% | 70.7% ± 13.3% | 70.9% ± 13.4% | 71.1% ± 12.7% | 0.124 |
| Ach-induced CAS | 382 (46.3%) | 731 (57.5%) | 772 (60.7%) | 566 (60.5%) | < 0.001 |
| Baseline spasm | 158 (19.2%) | 260 (20.4%) | 282 (22.2%) | 169 (18.1%) | 0.664 |
| ST-segment change | 17 (2.1%) | 49 (3.9%) | 43 (3.4%) | 30 (3.2%) | 0.152 |
| Chest pain | 365 (44.2%) | 585 (46.0%) | 596 (46.9%) | 381 (40.7%) | 0.171 |
| Atrioventricular block | 237 (28.7%) | 387 (30.4%) | 395 (31.1%) | 291 (31.1%) | 0.669 |
| Myocardial bridge | 179 (21.7%) | 250 (19.7%) | 204 (16.0%) | 134 (14.3%) | < 0.001 |
Data are presented as mean ± SD or as n (%). Ach: Acetylcholine; CAS: coronary artery spasm; DN: diameter narrowing; MD: minimal diameter; NTG: nitroglycerine; RD: reference diameter. *P < 0.001 by chi-square for linear trend among all groups.
Characteristics of acetylcholine provocation test in patients with significant coronary artery spasm.
| Variables | Group I (< 45 yrs) ( | Group II (45−54 yrs) ( | Group III (55−64 yrs) ( | Group IV(≥ 65 yrs) ( | |
| Maximal tolerable dose of Ach | |||||
| 20 µg/min | 15 (3.9%) | 37 (5.1%) | 43 (5.6%) | 27 (4.8%) | 0.675 |
| 50 µg/min | 106 (27.7%) | 246 (33.7%) | 280 (36.3%) | 201 (35.6%) | 0.05 |
| 100 µg/min | 261 (68.3%) | 447 (61.2%) | 448 (58.1%) | 336 (59.6%) | 0.008 |
| Spasm types | |||||
| Focal | 66 (17.3%) | 118 (16.1%) | 123 (15.9%) | 76 (13.4%) | 0.381 |
| Diffuse | 316 (82.7%) | 613 (83.9%) | 649 (84.1%) | 490 (86.6%) | 0.381 |
| Spasm vessel number | |||||
| One vessel | 273 (71.5%) | 489 (66.9%) | 508 (65.8%) | 399 (70.5%) | 0.119 |
| Multi-vessel | 109 (28.5%) | 242 (33.1%) | 264 (34.2%) | 167 (29.5%) | 0.119 |
| Spasm site | |||||
| LM | 2 (0.5%) | 2 (0.3%) | 2 (0.3%) | 1 (0.2%) | 0.797 |
| LAD | 257 (67.3%) | 440 (60.2%) | 462 (59.8%) | 383 (67.7%) | 0.570 |
| LCX | 15 (3.9%) | 39 (5.3%) | 43 (5.6%) | 16 (2.8%) | 0.072 |
| RCA | 1 (0.3%) | 10 (1.4%) | 2 (0.3%) | 0 | 0.012 |
| LCA + RCA | 2 (0.5%) | 1 (0.1%) | 4 (0.5%) | 0 | 0.220 |
Data are presented as n (%). Ach: acetylcholine; LAD: left anterior descending; LCA: left coronary artery; LCX: left circumflex; LM: left main; RCA: right coronary artery.
Univariate and multivariable logistic analysis of the predictors of acetylcholine induced coronary artery spasm.
| Variables | Univariate | Multivariate | Adjusted OR | 95% CI |
| Ages | ||||
| ≤ 45 yrs | < 0.001 | < 0.001 | ||
| 45−54 yrs | < 0.001 | 1.86 | 1.501−2.294 | |
| 55−64 yrs | < 0.001 | 2.40 | 1.920−2.988 | |
| ≥ 65 yrs | < 0.001 | 2.60 | 2.019−3.244 | |
| Male | < 0.001 | < 0.001 | 1.59 | 1.345−1.872 |
| Baseline spasm | < 0.001 | < 0.001 | 2.07 | 1.731−2.484 |
| Hypertension | 0.600 | 0.153 | 0.90 | 0.770−1.042 |
| Diabetes mellitus | 0.556 | 0.739 | 1.04 | 0.826−1.309 |
| Dyslipidemia | 0.012 | 0.316 | 1.01 | 0.906−1.357 |
| Smoking | < 0.001 | 0.079 | 1.08 | 0.979−1.477 |
| Myocardial bridge | < 0.001 | < 0.001 | 2.58 | 2.106−3.162 |
| hs-CRP | 0.327 | 0.485 | 1.00 | 0.995−1.010 |
| HDL cholesterol | < 0.001 | 0.285 | 0.997 | 0.992−1.002 |
hs-CRP: high sensitivity C reactive protein; HDL: high density lipoprotein.